Clinical Trial Update: A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA) [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 3, double-blind, placebo-controlled study evaluating solriamfetol for excessive daytime sleepiness in patients with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Excessive Daytime Sleepiness
• Obstructive Sleep Apnea

Drugs mentioned

• Solriamfetol (solriamfetol)

Snippet

Sponsor: Ignis Therapeutics (Suzhou) Limited | Conditions: Sleep Apnea, Obstructive, Excessive Daytime Sleepiness | Phase 3 | Status: COMPLETED